Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22694
Title: | Durvalumab induced sarcoid-like pulmonary lymphadenopathy. | Austin Authors: | Sanderson, Emma ;Wimaleswaran, Hari ;Senko, Clare ;White, Shane ;McDonald, Christine F | Affiliation: | Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Faculty of Medicine, Dentistry and Health Sciences University of Melbourne Melbourne VIC Australia |
Issue Date: | Apr-2020 | metadata.dc.date: | 2020-02-25 | Publication information: | Respirology case reports 2020; 8(3): e00542 | Abstract: | Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasing number of immune-related adverse events (irAEs) have been recognized with their use. To our knowledge, this is the first published case of sarcoid-like pulmonary lymphadenopathy associated with durvalumab, a monoclonal antibody against programmed death ligand-1 (PD-L1). A 76-year-old woman received adjuvant durvalumab for Stage IIA pT2aN1M0 (American Joint Committee on Cancer, Seventh edition) poorly differentiated lung adenocarcinoma. After three cycles, a sarcoid-like granulomatous reaction was identified in mediastinal and hilar lymph nodes. Although the lymphadenopathy remained stable in size with the ongoing treatment, progressive intracranial metastases were identified after a further three cycles of durvalumab. Sarcoid-like inflammation with the formation of non-caseating granulomas in the absence of systemic sarcoidosis is an irAE which may mimic disease progression. Although a subset of patients who experience this reaction may have a favourable response to checkpoint inhibition, progression of disease may occur contemporaneously. | URI: | http://ahro.austin.org.au/austinjspui/handle/1/22694 | DOI: | 10.1002/rcr2.542 | ORCID: | 0000-0001-6481-3391 0000-0002-4605-3891 |
Journal: | Respirology case reports | PubMed URL: | 32110415 | ISSN: | 2051-3380 | Type: | Journal Article | Subjects: | Durvalumab immune checkpoint inhibition sarcoidosis |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.